Shanghai-Based Hexaell Biotech Secures 50 million RMB ($7.3 million) Series A Financing From Hyfinity Investments

a Shanghai-based technology company specializing in bio-artificial liver organ based on hiHep cell engineering systems, closed the Series A round of 50 million RMB ($7.3 million) from Hyfinity Investm…
( read original story …)


Related Post